AAAAAA
Results:
1-12
|
Results: 12
Authors:
King, J
McLeod, J
Gonsette, RE
Duquette, P
Ebers, G
Rice, G
Francis, G
Lapierre, Y
Freedman, MS
Oger, J
Paty, D
Sorensen, PS
Pelletier, J
Hommes, OR
Jongen, PJH
Sanders, EACM
Andersen, O
Wollheim-Sandberg, M
Chofflon, M
Bates, D
Barnes, D
Blumhardt, LD
Hawkins, C
Hughes, RAC
Palace, J
Newsom-Davis, JM
Young, CA
Ammoury, N
Bacchi, M
Francis, G
Galazka, A
Hyde, R
Shah, S
Citation: J. King et al., Randomized controlled trial of interferon-beta-1a in secondary progressiveMS - Clinical results, NEUROLOGY, 56(11), 2001, pp. 1496-1504
Authors:
Sabbioni, MEE
Siegrist, HP
Bacchi, M
Bernhard, J
Castiglione, M
Thurlimann, B
Bonnefoi, H
Perey, L
Herrmann, R
Goldhirsch, A
Hurny, C
Citation: Mee. Sabbioni et al., Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment, BREAST CANC, 59(3), 2000, pp. 279-287
Authors:
Ribaudo, HJ
Bacchi, M
Bernhard, J
Thompson, SG
Citation: Hj. Ribaudo et al., A multilevel analysis of longitudinal ordinal data: evaluation of the level of physical performance of women receiving adjuvant therapy for breast cancer, J ROY STA A, 162, 1999, pp. 349-360
Authors:
Sabbioni, MEE
Castiglione, M
Hurny, C
Siegrist, HP
Bacchi, M
Bernhard, J
Thurlimann, B
Bonnefoi, H
Perey, L
Goldhirsch, A
Senn, HJ
Citation: Mee. Sabbioni et al., Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients, SUPP CARE C, 7(3), 1999, pp. 149-153
Authors:
Rochlitz, C
Lohri, A
Bacchi, M
Schmidt, M
Nagel, S
Fopp, M
Fey, MF
Herrmann, R
Neubauer, A
Citation: C. Rochlitz et al., Axl expression is associated with adverse prognosis and with expression ofBcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK), LEUKEMIA, 13(9), 1999, pp. 1352-1358
Authors:
Sieger, D
D'Addario, G
Lorenz, U
Bacchi, M
Thurlimann, B
Citation: D. Sieger et al., Dose escalation of carboplatin and cyclophosphamide supported by GM-CSF inthe treatment of patients with advanced ovarian cancer (FIGO III and IV) -a phase I study, ONKOLOGIE, 22(6), 1999, pp. 502-506
Authors:
Cocconi, G
Bella, M
Lottici, R
Leonardi, F
Ceci, G
Passalacqua, R
Di Blasio, B
Bordi, C
Biscottini, B
Melpignano, M
De Biasi, D
Finardi, C
Bacchi, M
Citation: G. Cocconi et al., Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma, AM J CL ONC, 22(6), 1999, pp. 559-567
Authors:
Borner, MM
Brousset, P
Pfanner-Meyer, B
Bacchi, M
Vonlanthen, S
Hotz, MA
Altermatt, HJ
Schlaifer, D
Reed, JC
Betticher, DC
Citation: Mm. Borner et al., Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 inprimary resected non-small cell lung cancer, BR J CANC, 79(5-6), 1999, pp. 952-958
Authors:
Chang, KL
Chen, YY
Chen, WG
Hayashi, K
Bacchi, C
Bacchi, M
Weiss, LM
Citation: Kl. Chang et al., EBNA-1 gene sequences in Brazilian and American patients with Hodgkin's disease, BLOOD, 94(1), 1999, pp. 244-250
Authors:
Chu, PG
Chang, KL
Chen, WG
Chen, YY
Shibata, D
Hayashi, K
Bacchi, C
Bacchi, M
Weiss, LM
Citation: Pg. Chu et al., Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations, AM J PATH, 155(3), 1999, pp. 941-947
Authors:
Bellini, R
Carrieri, M
Bacchi, M
Fonti, P
Celli, G
Citation: R. Bellini et al., Possible utilization of metallic copper to inhibit Aedes albopictus (Skuse) larval development, J AM MOSQ C, 14(4), 1998, pp. 451-456
Authors:
Roth, AD
Herrmann, R
Morant, R
Borner, MM
Honegger, HP
Obrist, R
Bacchi, M
Lange, J
Alberto, P
Castiglione, M
Citation: Ad. Roth et al., Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: The SAKK experience, EUR J CANC, 34(13), 1998, pp. 2126-2128
Risultati:
1-12
|